Biomarkører ved lungekreft
Lung Cancer Diagnostics Post COVID
- a Multidisciplinary View
August 26, 2020, 90min
Various diagnostic tools play indispensable roles in diagnosing, staging, treatment selection & monitoring of lung cancer patients. In this webinar Dr James Ho, University of Hong Kong, Dr Anand Sachithanandan, Sunway Medical Center Malaysia and Dr Takayuki Takahama,Kindai University Hospital Japanshare multidisciplinary perspectives on 1) how diagnostics algorithms including biomarkers and other testing modalities influence decisions on targeted therapy selection; 2) how COVID has impacted management of oncology patients.
Connecting Oncology and Pathology in the personalized care of NSCLC patients
November 13, 2020, 58min
Lung cancer remains one of the most difficult-to-treat cancers. Treatment landscape of NSCLC has been evolving dramatically in the past ten years, and biomarker testing is becoming increasingly complex. Discussion between oncologists and pathologists plays an integral role in biomarker-driven therapy options to select the right patient for the right treatment at the right time. In this webinar Prof Tony Mok,Chinese University of Hong Kong, and Prof Keith Kerr, University of Aberdeen, Scotland, .provide updates on treatment options in NSCLC, along with the oncology and pathology perspectives on molecular testing challenges and considerations in the clinical decision-making for lung cancer patients.
NTRK Rearrangements in Oncology: Diagnostic Strategies and Therapeutic Relevance
November 21, 2019, 61 minutter
Dr. Eric Konnick, University of Seattle, Washington, US. In this webinar, Dr. Konnick will discuss the biology, background and rationale for targeting TRK fusions. You will learn about the clinical evidence for TRK inhibitors and issues implementing pan-tumor assays, specifically pan-TRK assays.
EGFR Mutation in Lung Carcinoma
Apr 29 2019, 10 minutter
EGFR Mutation in Lung Carcinoma presented by Dr. Philippe Taniere, MD, PhD, University Hospital Birmingham, Birmingham, UK
Circulating perspectives: Multidisciplinary approaches to liquid biopsy in ALK-positive non-small-cell lung cancer
December 9, 2020, 62min
In this webinar Prof. Dr Holger Sültmann, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany, Prof. Dr Holger Sültmann, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany and Dr Petros Christopoulos, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany, discuss how liquid biopsy may be used for tumour profiling and share current developments of liquid biopsy-guided therapy for ALK-positive patients. They will also explore the role of liquid biopsy as a complementary test to tissue biopsy, and will look at the future of liquid biopsy as a potential tool to monitor treatment response and emerging recurrence in this patient group.